Optimizing risk-based breast cancer screening policies with reinforcement learning.
Adam Yala, Peter G Mikhael, Constance Lehman...
https://pubmed.ncbi.nlm.nih.gov/35027757/Actively Recruiting
Led by Azienda USL Reggio Emilia - IRCCS · Updated on 2026-05-07
2200
Participants Needed
1
Research Sites
78 weeks
Total Duration
Researchers are studying women at high risk of breast cancer, specifically those with a greater than 5% risk over the next five years, aged 35 to 60. The study aims to compare contrast-enhanced mammography CEM with the current standard of annual magnetic resonance imaging MRI combined with digital mammography DM to see if CEM can be a less expensive and quicker alternative for breast cancer detection. The trial will enroll about 1400 women and monitor breast cancer incidence and recall rates over two screening rounds, with a follow-up period of 2.5 years. Secondary goals include evaluating screening performance, safety, and patient compliance, with findings contributing to European breast cancer screening guidelines. Participants will be randomly assigned to receive two rounds of either CEM or MRIDM surveillance. After two years, all participants will undergo a final standard screening test used for high-risk women at their center. Imaging and assessments are timed with menstrual cycle phases for accuracy. Women unable to tolerate MRI or with specific genetic mutations may be assigned directly to one of the screening methods. Positive findings during screening may lead to further tests like ultrasound-guided biopsies or vacuum-assisted biopsies, with multidisciplinary review and follow-up. The study also includes quality control of imaging equipment, radiation dose monitoring, and retrospective image analysis. During the study, women will have regular visits every 12 months for screening and follow-up assessments. Imaging results will be interpreted locally by experienced radiologists, and additional ultrasound may be used as needed. Researchers will collect data on breast density, radiation exposure, adverse events, and recall rates. Advanced machine learning models will analyze images and clinical data to improve breast cancer risk prediction. The trial also involves cost and organizational impact studies, patient interviews, and systematic reviews to inform future screening guidelines. The total participation time includes two years of screening plus follow-up, with safety and efficacy outcomes measured at 12, 24, and up to 50 months.
CONDITIONS
Contrast Enhancement Mammography vs MRI for the Surveillance of Women at High Risk of Breast Cancer: Con-trust Randomized Controlled Trial
P
Paolo Giorgi Rossi, PhD, Specialization
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Azienda USL Reggio Emilia - IRCCS
Lead Sponsor
Istituto Oncologico Veneto I.O.V. - I.R.C.C.S.
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 12 months
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for detailed information and consent
Duration - 2 years
Participants undergo two rounds of breast cancer surveillance using either contrast-enhanced mammography (CEM) or magnetic resonance imaging (MRI) combined with digital mammography (DM), depending on their assigned group or contraindications. Imaging is performed during the indicated menstrual cycle phase. Positive or suspicious findings may lead to further assessment such as biopsy or ultrasound.
2 visits (in-person) for screening rounds spaced approximately 12 months apart
Duration - Single timepoint after 2 years
After 2 years, all participants who were randomized to either CEM or MRI undergo a final exit test, which is the standard surveillance test used for high-risk non-mutated women at each participating center.
1 visit (in-person) for exit test
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Adam Yala, Peter G Mikhael, Constance Lehman...
https://pubmed.ncbi.nlm.nih.gov/35027757/Marije F Bakker, Stéphanie V de Lange, Ruud M Pijnappel...
https://pubmed.ncbi.nlm.nih.gov/31774954/Amber N Hurson, Parichoy Pal Choudhury, Chi Gao...
https://pubmed.ncbi.nlm.nih.gov/34999890/Leslie R Lamb, Manisha Bahl
https://pubmed.ncbi.nlm.nih.gov/34286593/Koos van Geel, Ellen M Kok, Jorian P Krol...
https://pubmed.ncbi.nlm.nih.gov/31307654/Anna Rotili, Rubina Manuela Trimboli, Silvia Penco...
https://pubmed.ncbi.nlm.nih.gov/31938940/Francesco Sardanelli, Carla Boetes, Bettina Borisch...
https://pubmed.ncbi.nlm.nih.gov/20304629/Paola Armaroli, Alfonso Frigerio, Loredana Correale...
https://pubmed.ncbi.nlm.nih.gov/35689673/Geraldine J Liao, Leah C Henze Bancroft, Roberta M Strigel...
https://pubmed.ncbi.nlm.nih.gov/31004391/R P Thompson
https://pubmed.ncbi.nlm.nih.gov/3973840/Azienda USL Reggio Emilia - IRCCS
Lead Sponsor
Istituto Oncologico Veneto I.O.V. - I.R.C.C.S.
Collaborating Sponsor